AG: State joins drug settlement case
The that the Kansas Attorney General’s said in a news release Wednesday that a federal investigation found evidence that India-based Ranbaxy made and distributed 26 generic drugs that did not meet standards set by the U.S. Food and Drug Administration. The 26 drugs were manufactured in two plants in India and included prescription products intended for children, such as the antibiotic amoxicillin.
The settlement orders that about $324,000 be refunded to the Kansas Medicaid program.
Ranbaxy also entered into a consent decree with the federal government to address outstanding manufacturing quality and data integrity issues at the two manufacturing plants in India.